ZZ1-33

ZZ1-33 (also known as dCDK9) is a heterobifunctional proteolysis-targeting chimera (PROTAC) designed to induce the selective degradation of Cyclin-Dependent Kinase 9 (CDK9). It consists of a CDK9-binding moiety linked to a thalidomide-like ligand that recruits the Cereblon (CRBN) E3 ubiquitin ligase complex. This recruitment leads to the polyubiquitination and subsequent proteasomal degradation of CDK9. Developed by researchers at the Dana-Farber Cancer Institute, ZZ1-33 has demonstrated potent anti-tumor activity in preclinical models of multiple myeloma by triggering rapid cell death. Research into ZZ1-33 has also provided insights into mechanisms of resistance to CRBN-based degraders, highlighting the role of the CRBN complex and its regulators in degronimid efficacy.

Other names

dCDK9dCDK-9dCDK 9